Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer

• Status: Completed
• Trial end date: 2003-03-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: OSI Pharmaceuticals
• Treatments: Lurtotecan; Topotecan

Criteria

Inclusion Criteria:

• Confirmed relapsed ovarian cancer.

• Measurable disease greater than or equal to 20 mm (or greater than or equal to 10 mm on spiral CT scan).

• One or two prior regimens of chemotherapy. At least one regimen must have contained cisplatin or carboplatin.

• At least three weeks since prior chemotherapy and recovery from any related toxicities.

• At least four weeks since prior radiotherapy and recovery from any related toxicities.